YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)
Gleevec
Suffered from Gleevec Side Effects?
Gleevec has recently been linked to heart failure and other serious cardiac injuries. Gleevec, which is known generically as imatinib, is manufactured by Novartis and was approved by the FDA in 2001 to treat chronic myelogenous leukemia, or CML. In the first half of 2006, Gleevec generated $1.2 billion in revenue. Gleevec is the first member of a new class of agents that inhibit specific tyrosine kinase enzymes. In Europe, the drug is sold under the name Glivec and is approved to treat CML as well as gastrointestinal stromal tumors.The recent warning came after researchers found evidence that Gleevec caused heart failure in 10 patients. Rsearchers then tested Gleevec in lab dishes and in mice, both of which revealed the drug to be toxic to cardiac cells. Mice treated with Gleevec developed left ventricular dysfunction, one of the key symptoms of heart failure in which the heart fails to pump out blood completely. Heart failure is a serious and chronic condition that kills up to half of patients within five years.
If you or a loved one has suffered heart failure or any other cardiac injury after using Gleevec, you may have valuable legal rights. Contact Parker & Waichman, LLP today by completing the contact form on the right, or by calling 1-800-Law-Info (1-800-529-4636). An experienced drug side effects attorney will promptly evaluate your case for free.
GleevecRSS Feed
Another Gleevec Side Effect
Jun 20, 2008 | Parker Waichman Alonso LLP
French doctors have are now reporting a possible new side effect linked to Gleevec. Gleevec, generically known as imatinib, is a cancer drug most commonly used in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Earlier this year, a case report by Greek doctors suggested that imatinib may disrupt ovarian function and impair fertility.The French report appears in a letter published in the June 19 issue of the New England Journal of Medicine, wherein the...
"Miracle" Cancer Drug Gleevec Can Be Toxic To The Heart, Shows Jefferson Scientists
Jul 25, 2006 | www.medicalnewstoday.com
Gleevec, the wildly successful poster-child of a new generation of cancer drugs aimed at specific targets in the cancer cell, can be dangerous to the heart. Not only that, but other similarly based drugs called tyrosine kinase inhibitors could lead to heart problems as well, say researchers at the Center for Translational Medicine at Jefferson Medical College in Philadelphia. A team of scientists led by Thomas Force, M.D., James C. Wilson Professor of Medicine at Jefferson Medical College of...
Study: Cancer drug may pose heart danger
Jul 24, 2006 | AP
A successful cancer-fighting drug may also damage the heart, although a researcher says leukemia patients who need Gleevec should not abandon it. While effectively treating cancer, Gleevec can lead to heart failure in some patients, said Dr. Thomas Force, who teaches medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia. His study, published Sunday in the online edition of the journal Nature Medicine, was prompted by reports that 10 patients taking Gleevec for...
Case Review Form
Quick Facts
Gleevec Reference Guide
Generic Name
Imatinib
Date Approved
May 10, 2001
Manufacturer
Novartis
Status
On the market Approved Uses
Chronic myelogenous leukemia
Serious Side Effects
Heart failure
Other cardiac injuries Related Topics
Defective Drugs
Imatinib
Date Approved
May 10, 2001
Manufacturer
Novartis
Status
On the market Approved Uses
Chronic myelogenous leukemia
Serious Side Effects
Heart failure
Other cardiac injuries Related Topics
Defective Drugs
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS